Flucelvax Quadrivalent 2018-2019 Formula

Last updated on RxList: 10/19/2018
Flucelvax Quadrivalent 2018-2019 Formula Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 10/19/2018

Flucelvax Quadrivalent (Influenza Vaccine) Suspension for Intramuscular Injection 2018-2018 Formula is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine, approved for use in persons 4 years of age and older. Common side effects of Flucelvax Quadrivalent include:

  • injection site reactions (pain, redness, a hard lump, tenderness),
  • headache,
  • fatigue,
  • muscle pain,
  • chills,
  • vomiting,
  • diarrhea, and
  • irritability and changes in eating habits (in children 4 to 6 years).

The dose of Flucelvax Quadrivalent for 4 through 8 years of age is one or two doses, 0.5 mL each, administered at least 4 weeks apart. The dose of Flucelvax Quadrivalent for 9 years of age and older is one 0.5 mL dose. Flucelvax Quadrivalent may interact with other drugs or vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant before receiving Flucelvax Quadrivalent; it is unknown if it would affect a fetus. It is unknown if Flucelvax Quadrivalent passes into breast milk. Consult your doctor before breastfeeding.

Our Flucelvax Quadrivalent (Influenza Vaccine) Suspension for Intramuscular Injection 2018-2019 Formula Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

How to Get Rid of a Cold: Natural Remedies See Slideshow
Flucelvax Quadrivalent 2018-2019 Formula Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first shot.

Keep track of any and all side effects you have after receiving this vaccine. If you ever need to receive influenza virus vaccine in the future, you will need to tell your doctor if the previous shot caused any side effects.

Influenza virus injectable (killed virus) vaccine will not cause you to become ill with the flu virus that it contains. However, you may have flu-like symptoms at any time during flu season that may be caused by other strains of influenza virus.

Call your doctor at once if you have:

  • a light-headed feeling, like you might pass out;
  • severe weakness or unusual feeling in your arms and legs (may occur 2 to 4 weeks after you receive the vaccine);
  • high fever;
  • seizure (convulsions); or
  • unusual bleeding.

Common side effects may include:

  • low fever, chills;
  • mild fussiness or crying;
  • redness, bruising, pain, swelling, or a lump where the vaccine was injected;
  • headache, tired feeling; or
  • joint or muscle pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report vaccine side effects to the US Department of Health and Human Services at 1-800-822-7967.

Read the entire detailed patient monograph for Flucelvax Quadrivalent 2018-2019 Formula (Influenza Vaccine)

QUESTION

Which illness is known as a viral upper respiratory tract infection? See Answer
Flucelvax Quadrivalent 2018-2019 Formula Professional Information

SIDE EFFECTS

Clinical Trials Experience

The most common (≥10%) local and systemic reactions in adults 18 through 64 years of age were injection site pain (45.4%), headache (18.7%), fatigue (17.8%) and myalgia (15.4%), injection site erythema (13.4%), and induration (11.6%).

The most common (≥10%) local and systemic reactions in adults ≥65 years of age were injection site pain (21.6%), and injection site erythema (11.9%)

The most common (≥10%) local and systemic reactions in children 4 through 5 years of age after first dose of vaccine were tenderness at the injection site (46%), injection site erythema (18%), sleepiness (19%), irritability (16%), injection site induration (13%) and change in eating habits (10%).

The most common (≥10%) local and systemic reactions in children 6 through 8 years of age after first dose of vaccine were pain at the injection site (54%), injection site erythema (22%), injection site induration (16%), headache (14%), fatigue (13%) and myalgia (12%).

The most common (≥10%) local and systemic reactions in children and adolescents 9 through 17 years of age were pain at the injection site (58%), headache (22%), injection site erythema (19%), fatigue (18%) and myalgia (16%), and injection site induration (15%).

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a vaccine cannot be directly compared to rates in clinical studies of another vaccine, and may not reflect rates observed in clinical practice.

Adults 18 Years Of Age And Older

The safety of FLUCELVAX QUADRIVALENT in adults was evaluated in a randomized, doubleblind, controlled study conducted in the US (Study 1). The safety population included a total of 2680 adults 18 years of age and older; 1340 adults 18 through 64 years of age and 1340 adults 65 years of age and older.

In this study, subjects received FLUCELVAX QUADRIVALENT or one of the two formulations of comparator trivalent influenza vaccine (TIV1c and TIV2c) (FLUCELVAX QUADRIVALENT (n=1335), TIV1c, n=676 or TIV2c, n= 669). The mean age of subjects who received FLUCELVAX QUADRIVALENT was 57.4 years of age; 54.8% of subjects were female and 75.6% were Caucasian, 13.4% were Black, 9.1% were Hispanics, 0.7% were American Indian and 0.3%, 0.1% and 0.7% were Asian, Native Hawaiian and others, respectively.

The safety data observed are summarized in Table 2.

In this study, solicited local injection site and systemic adverse reactions were collected from subjects who completed a symptom diary card for 7 days following vaccination. Solicited adverse reactions for FLUCELVAX QUADRIVALENT and comparator are summarized in Table 2.

Table 2: Incidence of Solicited Adverse Reactions in the Safety Population1 Reported Within 7 Days of Vaccination (Study 1)

  18 through 64 years of age ≥ 65 years of age
Percentages (%)2
FLUCELVAX
QUADRIVALENT
N=663
Trivalent Influenza
Vaccine
FLUCELVAX
QUADRIVALENT
N=656
Trivalent Influenza
Vaccine
TIV1c
N=330
TIV2c
N=327
TIV1c
N=340
TIV2c
N=336
Local Adverse Reactions
Injection site induration 11.6 (0) 9.7 (0.3) 10.4 (0) 8.7 (0) 6.8 (0) 7.7 (0)
Injection site erythema 13.4 (0) 13.3 (0) 10.1 (0) 11.9 (0) 10.6 (0) 10.4 (0)
Injection site ecchymosis 3.8 (0) 3.3 (0.3) 5.2 (0) 4.7 (0) 4.4 (0) 5.4 (0)
Injection site pain 45.4 (0.5) 37.0 (0.3) 40.7 (0) 21.6 (0) 18.8 (0) 18.5 (0)
Systemic Adverse Reactions
Chills 6.2 (0.2) 6.4 (0.6) 6.4 (0) 4.4 (0.3) 4.1 (0.3) 4.5 (0.6)
Nausea 9.7 (0.3) 7.3 (0.9) 8.9 (1.2) 3.8 (0.2) 4.1 (0) 4.2 (0.3)
Myalgia 15.4 (0.8) 14.5 (0.9) 15.0 (1.2) 8.2 (0.2) 9.4 (0.3) 8.3 (0.6)
Arthralgia 8.1 (0.5) 8.2 (0) 9.5 (0.9) 5.5 (0.5) 5.0 (0.3) 6.8 (0.9)
Headache 18.7 (0.9) 18.5 (0.9) 18.7 (0.6) 9.3 (0.3) 8.5 (0.6) 8.3 (0.6)
Fatigue 17.8 (0.6) 22.1 (0.3) 15.6 (1.5) 9.1 (0.8) 10.6 (0.3) 8.9 (0.6)
Vomiting 2.6 (0) 1.5 (0.3) 0.9 (0) 0.9 (0.2) 0.3 (0) 0.6 (0)
Diarrhea 7.4 (0.6) 7.6 (0) 7.6 (0.6) 4.3 (0.5) 5.0 (0.9) 5.1 (0.3)
Loss of
appetite
8.3 (0.3) 8.5 (0.3) 8.3 (0.9) 4.0 (0.2) 5.0 (0) 3.6 (0.3)
Fever:
≥38.0 °C (≥40.0°C)
0.8 (0) 0.6 (0) 0.3 (0) 0.3 (0) 0.9 (0) 0.6 (0)
1 Safety population: all subjects in the exposed population who provided post-vaccination safety data
2 Percentage of severe adverse reactions are presented in parenthesis
Study 1: NCT01992094

Unsolicited adverse events were collected for 21 days after vaccination. In adults 18 years of age and older, unsolicited adverse events were reported in 16.1% of subjects who received FLUCELVAX QUADRIVALENT, within 21 days after vaccination.

In adults 18 years of age and older, serious adverse events (SAEs) were collected throughout the study duration (until 6 months after vaccination) and were reported by 3.9%, of the subjects who received FLUCELVAX QUADRIVALENT. None of the SAEs were assessed as being related to study vaccine.

Children And Adolescents 4 Through 17 Years Of Age

The safety of FLUCELVAX QUADRIVALENT in children was evaluated in a randomized, double-blind, controlled study conducted in the US (Study 2). The safety population included a total of 2332 children 4 through 17 years of age; 1161 children 4 through 8 years of age and 1171 children 9 through 17 years of age.

In this study, subjects received FLUCELVAX QUADRIVALENT or one of the two formulations of comparator trivalent influenza vaccine (FLUCELVAX QUADRIVALENT n=1159, TIV1c, n=593 or TIV2c, n= 580). Children 9 through 17 years of age received a single dose of FLUCELVAX QUADRIVALENT or comparator vaccine. Children 4 through 8 years of age received one or two doses (separated by 4 weeks) of FLUCELVAX QUADRIVALENT or comparator vaccine based on determination of the subject’s prior influenza vaccination history. The mean age of subjects who received FLUCELVAX QUADRIVALENT was 9.6 years of age; 48% of subjects were female and 53% were Caucasian. The safety data observed are summarized in Table 3 and Table 4.

In this study, solicited local injection site and systemic adverse reactions were collected from subjects who completed a symptom diary card for 7 days following vaccination. Solicited adverse reactions for FLUCELVAX QUADRIVALENT and comparator are summarized in Table 3 and Table 4.

Table 3: Incidence of Solicited Adverse Reactions in the Safety Population1 (4 through 5 years of age) Reported Within 7 Days of the First dose of Vaccination (Study 2)

  Children 4 through 5 years
Percentages (%)2
FLUCELVAX
QUADRIVALENT
N=182
Trivalent Influenza Vaccine
TIV1c N=91 TIV2c N=93
Local Adverse Reactions
Injection site induration 13 (1) 20 (2) 13 (0)
Injection site erythema 18 (1) 23 (1) 17 (0)
Injection site ecchymosis 9 (0) 11 (0) 8 (0)
Injection site tenderness 46 (1) 45 (1) 43 (0)
Systemic Adverse Reactions
Change in eating habits 10 (1) 7 6
Sleepiness 19 (1) 12 (3) 10 (0)
Irritability 16 (2) 10 (2) 10 (1)
Chills 5 (1) 2 (0) 1 (0)
Vomiting 4 (0) 2 (0) 2 (0)
Diarrhea 4 (0) 2 (0) 2 (0)
Fever: ≥38.0 °C (≥40.0 °C) 4 (0) 4 (0) 3 (0)
1 Safety population: all subjects in the exposed population who provided post-vaccination safety data.
2 Percentage of subjects with severe adverse reactions are presented in parenthesis.
Study 2: NCT01992107

Table 4: Incidence of Solicited Adverse Reactions in the Safety Population1 (Children 6 through 17 years of age) Reported Within 7 Days of Vaccination (Study 2)

  Children 6 through 8 years
(after first dose)
Children 9 through 17 years
Percentages (%)2
FLUCELVAX
QUADRIVALENT
N=371- 372
Trivalent Influenza
vaccine
FLUCELVAX
QUADRIVALENT
N=579
Trivalent Influenza
Vaccine
TIV1c
N=185
TIV2c
N=186
TIV1c
N=294
TIV2c
N=281- 282
Local Adverse Reactions
Injection site induration 16 (0) 19 (1) 13 (0) 15 (0) 15 (0) 13 (<1)
Injection site erythema 22 (0) 23 (1) 20 (0) 19 (<1) 17 (0) 15 (<1)
Injection site ecchymosis 9 (0) 9 (0) 8 (0) 4 (0) 5 (0) 5 (0)
Injection site pain 54 (1) 57 (1) 58 (2) 58 (1) 51(<1) 50 (0)
Systemic Adverse Reactions
Chills 4 (1) 3 (0) 4 (0) 7 (0) 6 (1) 4 (1)
Nausea 8 (1) 5 (0) 5 (1) 9 (<1) 8 (1) 7 (1)
Myalgia 12 (1) 14 (0) 10 (0) 16 (<1) 17 (<1) 15 (<1)
Arthralgia 4 (0) 5 (0) 4 (0) 6 (0) 6 (0) 8 (<1)
Headache 14 (1) 13 (0) 12 (0) 22 (1) 23 (2) 18 (1)
Fatigue 13 (2) 14 (0) 18 (0) 18 (<1) 16 (1) 16 (<1)
Vomiting 3 (1) 3 (0) 3 (0) 2 (0) 1 (0) 2 (0)
Diarrhea 3 (<1) 6 (1) 5 (0) 4 (0) 4 (0) 3 (<1)
Loss of
appetite
9 (<1) 5 (0) 8 (1) 9 (0) 9 (<1) 9 (0)
Fever:
≥38.0 °C (≥40.0 °C)
4 (0) 3 (0) 2 (0) 1 (<1) 3 (0) 1 (0)
1 Safety population: all subjects in the exposed population who provided post-vaccination safety data.
2 Percentage of subjects with severe adverse reactions are presented in parenthesis.
Study 2: NCT 01992107

In children who received a second dose of FLUCELVAX QUADRIVALENT, TIV1c, or TIV2c, the incidence of adverse reactions following the second dose of vaccine were similar to those observed with the first dose.

Unsolicited adverse events were collected for 21 days after last vaccination. In children 4 through 17 years of age, unsolicited adverse events were reported in 24.3% of subjects who received FLUCELVAX QUADRIVALENT, within 3 weeks after last vaccination.

In children 4 through 17 years of age, serious adverse events (SAEs) were collected throughout the study duration (until 6 months after last vaccination) and were reported by 0.5% of the subjects who received FLUCELVAX QUADRIVALENT. None of the SAEs were assessed as being related to study vaccine.

Postmarketing Experience

The following additional adverse events have been identified during post-approval use of FLUCELVAX QUADRIVALENT. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.

Immune system disorders: Allergic or immediate hypersensitivity reactions, including anaphylactic shock.

Nervous systems disorders: Syncope, presyncope, paresthesia.

Skin and subcutaneous tissue disorders: Generalized skin reactions including pruritus, urticaria or non-specific rash.

General disorders and administration site conditions: Extensive swelling of injected limb.

Read the entire FDA prescribing information for Flucelvax Quadrivalent 2018-2019 Formula (Influenza Vaccine)

© Flucelvax Quadrivalent 2018-2019 Formula Patient Information is supplied by Cerner Multum, Inc. and Flucelvax Quadrivalent 2018-2019 Formula Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors